Tagrisso™
Active ingredients: Osimertinib
Consumer medicine information
Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.
Listen to the audio transcription of the CMI leaflet.
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
TAGRISSO as monotherapy is indicated:, as adjuvant therapy after tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations, as detected by a validated test., the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have activating EGFR mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy., for the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have activating EGFR mutations, as detected by a validated test., for the treatment of patients with locally advanced or metastatic NSCLC that is EGFR T790M mutation-positive, as detected by a validated test.,TAGRISSO is indicated in combination with:, pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations.
Source: ARTG
Storage conditions
- Shelf lifetime is 36 Months
- Store below 30 degrees Celsius
- Protect from direct sunlight
Source: ARTG
How to use this medicine
Non-composite pack
This medicine contains one component only.
Component
- Tablet, film coated
- Oral
- The 40 mg tablets are round, biconvex, beige, film-coated tablets with a diameter of approximately 9 mm. The tablets are debossed with AZ over 40 on one side and plain on the reverse
Source: ARTG
Images

Images © Medicines Information Pty Ltd.
Do I need a prescription?
These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.
- 30
Source: ARTG
Is this medicine subsidised?
This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 November 2026, under the following PBS item codes:
- 12233W (Opens in new tab)
- 11620N (Opens in new tab)
- 14162J (Opens in new tab)
- 15378J (Opens in new tab)
Ask your pharmacist or doctor about your eligibility
Source: PBS
Pregnant or planning a pregnancy?
For the active ingredient: Osimertinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Source: AHT
Reporting side effects
If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).
You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)
Source: ARTG
Data sources
- Australian Health Thesaurus (AHT) (Opens in new tab) – Last updated on 4 November 2026
- Australian Medicines Terminology (AMT) (Opens in new tab) – Last updated on 4 November 2026
- Australian Register of Therapeutic Goods (ARTG) (Opens in new tab) – Last updated on 4 November 2026
- Pharmaceutical Benefits Scheme (PBS) (Opens in new tab) – Last updated on 4 November 2026
- Medicines Information Pty Ltd (Opens in new tab) – Last updated on 4 November 2026
Disclaimer
Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).
Symptom Checker
Worried about your health?
Select a symptom, answer some questions, get advice

